<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F31D4A66-92AA-4002-BD5A-B0E539ACF08F"><gtr:id>F31D4A66-92AA-4002-BD5A-B0E539ACF08F</gtr:id><gtr:name>Mount Sinai Hospital (USA)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/468F2797-5295-4912-BDED-8F3402CE246A"><gtr:id>468F2797-5295-4912-BDED-8F3402CE246A</gtr:id><gtr:name>New York University</gtr:name><gtr:address><gtr:line1>7 East 12th Street</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:department>Division of Radiotherapy and Imaging</gtr:department><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F31D4A66-92AA-4002-BD5A-B0E539ACF08F"><gtr:id>F31D4A66-92AA-4002-BD5A-B0E539ACF08F</gtr:id><gtr:name>Mount Sinai Hospital (USA)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/468F2797-5295-4912-BDED-8F3402CE246A"><gtr:id>468F2797-5295-4912-BDED-8F3402CE246A</gtr:id><gtr:name>New York University</gtr:name><gtr:address><gtr:line1>7 East 12th Street</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/DB09A3ED-2068-4491-8C53-6830B2CDF9C1"><gtr:id>DB09A3ED-2068-4491-8C53-6830B2CDF9C1</gtr:id><gtr:firstName>Penelope</gtr:firstName><gtr:surname>Hopwood</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/303A1CBE-C778-4A59-B054-0BB30FE04502"><gtr:id>303A1CBE-C778-4A59-B054-0BB30FE04502</gtr:id><gtr:firstName>Judith</gtr:firstName><gtr:surname>Bliss</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2A940A47-40A7-4C63-AE8E-7EFD3D48728E"><gtr:id>2A940A47-40A7-4C63-AE8E-7EFD3D48728E</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Yarnold</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G9600656"><gtr:id>69D5C7AB-944F-4B88-AD2F-5FB3C6905857</gtr:id><gtr:title>Standardisation of Radiotherapy (START) Trial</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G9600656</gtr:grantReference><gtr:abstractText>The patient advocate group Radiotherapy Action Group Exposure (R.A.G.E.) has become a strong supporter of the START initiative over the years, with 2 members represented on the Trial Management Group. Issues relating to radiotherapy fractionation have emerged repeatedly in the media over the last 20 years. The understanding of scientific issues by the majority of lay people and a minority of professionals has been poor. The trial has achieved a high public profile across the UK including a discussion on Panorama. A highly productive debate has changed the climate, with the importance of evidence based medicine acknowledged by all parties.</gtr:abstractText><gtr:technicalSummary>Breast radiotherapy is delivered as a series of small 
doses (fractions). The international standard delivers
25 fractions of 2.0 Gy over 5 weeks (Gy = unit of 
radiation dose). Alternative UK schedules give a 
smaller number of slightly larger fractions e.g. 
15 fractions of 2.67 Gy over 3 weeks. 
If simpler schedules prove to be at least as safe 
and effective as the international standard, their 
adoption will benefit patients and health services. 
The START trial tests the hypothesis that schedules 
using fractions slightly larger than 2.0 Gy are safe 
and effective alternatives to the international 
standard.</gtr:technicalSummary><gtr:fund><gtr:end>2009-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1997-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2079377</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Public Health England</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Public Health England Porton Down</gtr:department><gtr:description>The Relationship Between Homologous Recombination Repair and the Sensitivity of Human Epidermis to the Size of Daily Doses Over a 5-Week Course of Breast Radiotherapy</gtr:description><gtr:id>3A0805B5-472C-4F5E-AE4E-3F5E5CF9F6D5</gtr:id><gtr:impact>PMID: 22855580
PMID: 23746696</gtr:impact><gtr:outcomeId>58be8c81ecb178.25196840-2</gtr:outcomeId><gtr:partnerContribution>Partners were responsible for the laboratory aspects of this correlative research</gtr:partnerContribution><gtr:piContribution>The research plan was designed by me, and the breast cancer patients contributing serial skin biopsies to the research were treated under my care. 
A clinical research fellow collected the skin samples and analysed them at Oxford and Didcot as part of her PhD degree</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Oncology</gtr:department><gtr:description>The Relationship Between Homologous Recombination Repair and the Sensitivity of Human Epidermis to the Size of Daily Doses Over a 5-Week Course of Breast Radiotherapy</gtr:description><gtr:id>3EEF9717-2643-4AD2-A2B7-81405324C4A7</gtr:id><gtr:impact>PMID: 22855580
PMID: 23746696</gtr:impact><gtr:outcomeId>58be8c81ecb178.25196840-1</gtr:outcomeId><gtr:partnerContribution>Partners were responsible for the laboratory aspects of this correlative research</gtr:partnerContribution><gtr:piContribution>The research plan was designed by me, and the breast cancer patients contributing serial skin biopsies to the research were treated under my care. 
A clinical research fellow collected the skin samples and analysed them at Oxford and Didcot as part of her PhD degree</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mount Sinai Hospital (USA)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>NIH 01: A genome wide association study for the identification of radiation-induced normal tissue toxicity in breast cancer patients treated with radiotherapy</gtr:description><gtr:id>65D437AD-B6E3-4B26-91F9-B7FDE47D8909</gtr:id><gtr:impact>This grant application was rejected but we are intending reapplying in 2011.</gtr:impact><gtr:outcomeId>16AD5C118B0-1</gtr:outcomeId><gtr:partnerContribution>Co-applicant on an NIH grant application.Co-applicant on an NIH grant application.</gtr:partnerContribution><gtr:piContribution>We have jointly submitted this grant application to the NIH in America.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>New York University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>School of Medicine</gtr:department><gtr:description>NIH 01: A genome wide association study for the identification of radiation-induced normal tissue toxicity in breast cancer patients treated with radiotherapy</gtr:description><gtr:id>A4F57BC3-F653-4254-8592-358D1E164A95</gtr:id><gtr:impact>This grant application was rejected but we are intending reapplying in 2011.</gtr:impact><gtr:outcomeId>16AD5C118B0-2</gtr:outcomeId><gtr:partnerContribution>Co-applicant on an NIH grant application.Co-applicant on an NIH grant application.</gtr:partnerContribution><gtr:piContribution>We have jointly submitted this grant application to the NIH in America.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Public Health England</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>DNA double-strand break repair and induction of apoptosis in ex vivo irradiated blood lymphocytes in relation to late normal tissue reactions following breast radiotherapy</gtr:description><gtr:id>328078EB-B561-4B7C-B607-8C1FAB227110</gtr:id><gtr:impact>PMID: 21620495
PMID: 21704405
PMID: 24622963
PMID: 26944319
PMID: 27106550
PMID: 27197782</gtr:impact><gtr:outcomeId>58be8e26c03986.03131716-1</gtr:outcomeId><gtr:partnerContribution>A clinical research fellow performed the laboratory assays as part of his PhD.</gtr:partnerContribution><gtr:piContribution>I drafted the original research proposal, and the research subjects were patients under my care who has participated in national clinical trial led by myself. My team also collected the blood samples for fresh transport to Didcot</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Press release from CRUK</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>878A0C23-DE98-4AB8-9BC3-FF73B812F66A</gtr:id><gtr:impact>This was a press release from the funders to accompany the 10 year results of the START trial when published in Lancet Oncology

Lots of coverage of the trial results in the national press.</gtr:impact><gtr:outcomeId>R9oSGrDfHYZ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>San Antonio Breast Cancer Conference 2012</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7F8F9E52-DFF2-48AE-B469-C1A1364F2DD6</gtr:id><gtr:impact>The conference attracts nearly 10000 participants from 100 countries, all breast cancer specialists. The abtract title and authors are:
The UK START (Standardisation of Breast Radiotherapy) Trials; 10-year follow-up results. Joanne S Haviland, Rajiv Agrawal, Edwin Aird, Jane Barrett, Peter Barrett-Lee, Jackie Brown, John Dewar, Jane Dobbs, Penelope Hopwood, Peter Hoskin, Pat Lawton, Brian Magee, Judith Mills, David Morgan, Roger Owen, Joyce Pritchard, Sandra Simmons, Mark Sydenham, Karen Venables, Judith M Bliss, John R Yarnold.

The results of the START trial will be used in a meta analysis with other hypofractionation trials.</gtr:impact><gtr:outcomeId>M9nQmBKuuk8</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ECC 2013 press release</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>17F80D3D-79FC-48B2-B6AA-72E9A42DAE2D</gtr:id><gtr:impact>The organisers of the conference ECC2013 decided to release a press statement for the poster presentation as the results were thought to be highly significant for the radotherapy community.

There was a lot of press coverage for the results of this poster.</gtr:impact><gtr:outcomeId>daDxhJAaCHz</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release to accompany ASCO presentation</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CAA19C4F-C4E0-4C53-8ED7-DB49082D54E3</gtr:id><gtr:impact>The START trial presentation was selected for ASCO press coverage, which comprised a press conference and a press release. This is only for those presentations considered &amp;quot;Best at ASCO&amp;quot;.

We were approached by Lancet to pubish the results in their journal.</gtr:impact><gtr:outcomeId>80C9AA0D2DA</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press Release San Antonio Dec 2012</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>05ADEAF3-5873-4539-A92B-BB03B25921EF</gtr:id><gtr:impact>The START trial 10 year results were chosen by the San Antonio Conference for their press conference.

The press conference was attended by press from North America and Europe</gtr:impact><gtr:outcomeId>U7nhvwWau5A</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Poster presentation at European Cancer Congress 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>38B209DF-38E2-4517-98BC-9B9930B3005D</gtr:id><gtr:impact>The poster was selected for a poster presentation at ECC 2013 and presented important results about wasted radiotherapy dose during treatment for breast cancer. The title and authors of the poster were: Estimation of an overall treatment time factor for local relapse after adjuvant radiotherapy for early breast cancer in the START hypofractionation trials (CRUK/96/001); JS Haviland, SM Bentzen, M Sydenham, JR Owen, JM Bliss, JR Yarnold on behalf of the START Trialists' Group.

There was a lot of press coverage of these results.</gtr:impact><gtr:outcomeId>HQfkFf8TwKv</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lancet Oncology press release</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4C45A524-2ACA-491D-BDE6-31A4E0A96AE0</gtr:id><gtr:impact>This was the press release for the 10 year results of the START trial which was written by Lancet Oncology.

There were a lot of articles in national press.</gtr:impact><gtr:outcomeId>hu5bVFFF8pg</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lay Summary for patients</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9EE5D38D-DAAE-4D45-B058-FD7781F3AD6E</gtr:id><gtr:impact>We wrote a lay summary of the published trial results for the participants in the trial. This was then circulated to the recruiting centres to send or give out to the patients.

We are not aware of any impact of this policy.</gtr:impact><gtr:outcomeId>2504B8EC74F</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>27179</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR Research Capability Funding</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>49D06616-B845-4BED-BCF0-814074365AC4</gtr:id><gtr:outcomeId>bjuyg1vX7mX</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>230000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Trials Award - HOT II/Cancer Research UK (CRUK) and Department of Health</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>C181/A9694</gtr:fundingRef><gtr:id>C3253EB2-64A4-47E9-BBD4-379D86171658</gtr:id><gtr:outcomeId>YSUk8zwqFGq1</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>126783</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Translational Grant - RACE(S)</gtr:description><gtr:end>2008-04-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C181/A6976</gtr:fundingRef><gtr:id>67F6637A-46A5-424B-9188-E3400412208C</gtr:id><gtr:outcomeId>AYK63SkWZv10</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>234385</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Trials Award - HOT II/Cancer Research UK (CRUK) and Department of Health</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C181/A9694</gtr:fundingRef><gtr:id>8347EF1C-917E-4BD7-8A87-3C17615F7E2A</gtr:id><gtr:outcomeId>YSUk8zwqFGq0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>182524</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Health Protection Agency</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>Public Health England</gtr:fundingOrg><gtr:id>FA8A526B-C782-4A07-BFC9-782E89CE8D15</gtr:id><gtr:outcomeId>EWWdhtB7gXZ</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>CTAAC Clinical Trials Advisory &amp; Awards</gtr:department><gtr:description>Clinical Trials Awards &amp;amp; Advisory Committee - Late Phase Study</gtr:description><gtr:end>2020-07-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C1491/A16831</gtr:fundingRef><gtr:id>2B1D1D2D-84EE-4D14-9B11-365BED7C5FD9</gtr:id><gtr:outcomeId>skyw3QpxsS7</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>185500</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EC FP6 (EURATOM)</gtr:description><gtr:end>2009-08-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:fundingRef>FI6R-036452</gtr:fundingRef><gtr:id>147F4648-E58D-4C42-949E-BAE54D207838</gtr:id><gtr:outcomeId>12055C1F0400</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2006-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3639054</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Health Technology Assessment Programme (HTA)</gtr:department><gtr:description>NIHR Health Technology Assessment programme FAST-Forward</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>09/01/47</gtr:fundingRef><gtr:id>5133635B-2A33-4678-90A1-6CBEA2FA75A7</gtr:id><gtr:outcomeId>W7g6eHmdvGq0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>160257</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Grant</gtr:description><gtr:end>2010-02-02</gtr:end><gtr:fundingOrg>Breast Cancer Campaign (BCC)</gtr:fundingOrg><gtr:fundingRef>PR11</gtr:fundingRef><gtr:id>179D16FF-5C7C-4A9C-A5A0-D62700B7765E</gtr:id><gtr:outcomeId>b6Btk8Qg2qy0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation in Cochrane Review</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>4D4D3BBC-5E9C-40EB-BDA6-6ADE0A82FC38</gtr:id><gtr:impact>The new radiotherapy regimen delivers a curative post-surgical treatment for localised breast cancer that is gentler on the healthy tissues and non-inferior in terms of cancer cure.
A shorter treatment regimen has allowed more patients to be treated at radiotherapy centres. 
It has also saved the NHS money as many fewer treatment sessions have been needed.</gtr:impact><gtr:outcomeId>73559AD4AEE</gtr:outcomeId><gtr:type>Citation in systematic reviews</gtr:type><gtr:url>http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003860.pub4/abstract</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>This is a clinical trial testing hypofractionated radiotherapy for the treatment of early breast cancer.</gtr:description><gtr:id>05B0E7B6-A5D8-4F3D-BD81-6E1E4F65FB13</gtr:id><gtr:impact>The reduced fractionation in the START trials is now UK standard of care.</gtr:impact><gtr:outcomeId>rY33taxS2cQ</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>START clinical trial</gtr:title><gtr:type>Therapeutic Intervention - Radiotherapy</gtr:type></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>4BF3A84F-6EC7-456D-8AD6-700E4FC99DF9</gtr:id><gtr:title>Late effects of breast radiotherapy.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86024c1d9431f553e3e1d02c4cc95031"><gtr:id>86024c1d9431f553e3e1d02c4cc95031</gtr:id><gtr:otherNames>Haviland JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>5aa11fd6a03c40.22196757</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E889A44-9C75-42BE-8C32-00DEBD51AE6A</gtr:id><gtr:title>The UK HeartSpare Study (Stage IB): randomised comparison of a voluntary breath-hold technique and prone radiotherapy after breast conserving surgery.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e22b1d43bc12a5173d191f77a36766b"><gtr:id>5e22b1d43bc12a5173d191f77a36766b</gtr:id><gtr:otherNames>Bartlett FR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>5aa11fd3ab9604.74545862</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>589DF5CE-BA9B-487A-B5C2-D88F11FB6794</gtr:id><gtr:title>Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86024c1d9431f553e3e1d02c4cc95031"><gtr:id>86024c1d9431f553e3e1d02c4cc95031</gtr:id><gtr:otherNames>Haviland JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>5a7b2d49da86b4.26617191</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9E2783D-4076-4CB0-A1C4-FDED70EC6071</gtr:id><gtr:title>Evaluation of a method for grading late photographic change in breast appearance after radiotherapy for early breast cancer.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86024c1d9431f553e3e1d02c4cc95031"><gtr:id>86024c1d9431f553e3e1d02c4cc95031</gtr:id><gtr:otherNames>Haviland JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>C293463BC68</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F07D336-A3BD-41B5-94BA-049176666A1F</gtr:id><gtr:title>Do Patient-reported Outcome Measures Agree with Clinical and Photographic Assessments of Normal Tissue Effects after Breast Radiotherapy? The Experience of the Standardisation of Breast Radiotherapy (START) Trials in Early Breast Cancer.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86024c1d9431f553e3e1d02c4cc95031"><gtr:id>86024c1d9431f553e3e1d02c4cc95031</gtr:id><gtr:otherNames>Haviland JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>56c351c328f183.36614260</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1EA485CB-CFD5-4BF3-A6CF-D4861D973F11</gtr:id><gtr:title>Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8dbd9120b92f3f8653e21fa8425b50c7"><gtr:id>8dbd9120b92f3f8653e21fa8425b50c7</gtr:id><gtr:otherNames>EBCTCG (Early Breast Cancer Trialists' Collaborative Group)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>5aa11fd738d646.23700493</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6A0B52C-B5B6-4B56-91DE-F00C48C8482B</gtr:id><gtr:title>Normal tissue complication probability (NTCP) parameters for breast fibrosis: pooled results from two randomised trials.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7a59e1f40bd4e6892376678e5aaea96"><gtr:id>c7a59e1f40bd4e6892376678e5aaea96</gtr:id><gtr:otherNames>Mukesh MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>5aa11e9b209614.64815135</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F58695F-481D-4F71-AD7C-236F25A78725</gtr:id><gtr:title>Prolongation of overall treatment time as a cause of treatment failure in early breast cancer: An analysis of the UK START (Standardisation of Breast Radiotherapy) trials of radiotherapy fractionation.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86024c1d9431f553e3e1d02c4cc95031"><gtr:id>86024c1d9431f553e3e1d02c4cc95031</gtr:id><gtr:otherNames>Haviland JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>589a227c5ad895.90298701</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6AE678B-0698-4E1F-8D36-306B941F644C</gtr:id><gtr:title>Where Do We Look for Markers of Radiotherapy Fraction Size Sensitivity?</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b0e489750c6d225b340afa2b876064f7"><gtr:id>b0e489750c6d225b340afa2b876064f7</gtr:id><gtr:otherNames>Somaiah N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>56cd8e783559c5.40288622</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CFA534C-28FC-4108-90A9-D8B11A0AB1E5</gtr:id><gtr:title>DNA double-strand break repair and induction of apoptosis in ex vivo irradiated blood lymphocytes in relation to late normal tissue reactions following breast radiotherapy.</gtr:title><gtr:parentPublicationTitle>Radiation and environmental biophysics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/170b302e670a95b5871e74042c8161dc"><gtr:id>170b302e670a95b5871e74042c8161dc</gtr:id><gtr:otherNames>Chua ML</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0301-634X</gtr:issn><gtr:outcomeId>5aa11fd7978c57.68973625</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15780368-C344-4870-BA15-A96F0DB240C7</gtr:id><gtr:title>XRCC1 Polymorphism Associated With Late Toxicity After Radiation Therapy in Breast Cancer Patients.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71b750891f077fec864d26bebbcfb7bf"><gtr:id>71b750891f077fec864d26bebbcfb7bf</gtr:id><gtr:otherNames>Seibold P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>56cd8e448c3411.04714328</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C26AA95-AD50-4C24-8136-CF6B96BAD7C9</gtr:id><gtr:title>Changes in mast cell number and stem cell factor expression in human skin after radiotherapy for breast cancer.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/840ef5fc992da770f0f63449f3d0f63a"><gtr:id>840ef5fc992da770f0f63449f3d0f63a</gtr:id><gtr:otherNames>Westbury CB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>5aa11fd6d7aa01.21245035</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5A7DFC2-1A08-47BB-A850-1FBB17C4C2E4</gtr:id><gtr:title>A toast to the silver anniversary of Clinical Oncology: a quarter of a century of advances in evidence-based radiation dose fractionation.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11904e642cd763ff09e26ce4d963c4be"><gtr:id>11904e642cd763ff09e26ce4d963c4be</gtr:id><gtr:otherNames>Bentzen SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>5aa11fd3de56a4.87052572</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82510905-5C28-4B2B-A80B-6189D847C9EA</gtr:id><gtr:title>Breast radiotherapy: less is more?</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4da0e2ef9b0cc75e7cb034fd9e00a0cb"><gtr:id>4da0e2ef9b0cc75e7cb034fd9e00a0cb</gtr:id><gtr:otherNames>Coles CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>5aa11e9c087974.29746162</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2AC39B1E-4F44-4A98-8B62-B457EADA0A43</gtr:id><gtr:title>Breast radiotherapy and heart disease - where are we now?</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e22b1d43bc12a5173d191f77a36766b"><gtr:id>5e22b1d43bc12a5173d191f77a36766b</gtr:id><gtr:otherNames>Bartlett FR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>5aa11e9ae4e0b3.46273226</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72B6595C-F747-4560-ACBC-F0760735CF1B</gtr:id><gtr:title>Patient reported outcomes following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials. Presented on behalf of the START Trial Management Group</gtr:title><gtr:parentPublicationTitle>European Journal of Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d2a785ff36a73dbabb9a12771c5e73e"><gtr:id>9d2a785ff36a73dbabb9a12771c5e73e</gtr:id><gtr:otherNames>Griffin C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>58ad6fe22689a7.79294368</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DFB7A70F-CCCB-4F8C-8851-AE292DF19158</gtr:id><gtr:title>Voluntary breath-hold technique for reducing heart dose in left breast radiotherapy.</gtr:title><gtr:parentPublicationTitle>Journal of visualized experiments : JoVE</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e22b1d43bc12a5173d191f77a36766b"><gtr:id>5e22b1d43bc12a5173d191f77a36766b</gtr:id><gtr:otherNames>Bartlett FR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1940-087X</gtr:issn><gtr:outcomeId>5aa11fd5351301.17287615</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>518AD6CB-89D4-4B57-B56D-5DBFE378EDE7</gtr:id><gtr:title>The UK HeartSpare Study (Stage II): Multicentre Evaluation of a Voluntary Breath-hold Technique in Patients Receiving Breast Radiotherapy.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e22b1d43bc12a5173d191f77a36766b"><gtr:id>5e22b1d43bc12a5173d191f77a36766b</gtr:id><gtr:otherNames>Bartlett FR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>5aa11fd35d6db0.74734528</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08C7637A-2A74-40C4-9A61-ABFBE1CBD629</gtr:id><gtr:title>What is the optimum breast plan: a study based on the START trial plans.</gtr:title><gtr:parentPublicationTitle>The British journal of radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f9d854988cf3675d94896a0e22fdfe4"><gtr:id>8f9d854988cf3675d94896a0e22fdfe4</gtr:id><gtr:otherNames>Venables K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0007-1285</gtr:issn><gtr:outcomeId>F1E333D51B5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9EA544D7-29F5-48F2-B15E-074C32A25F2D</gtr:id><gtr:title>Radiotherapy for breast cancer, the TARGIT-A trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/580e6eb65d401ba7b3943179f1d0ad35"><gtr:id>580e6eb65d401ba7b3943179f1d0ad35</gtr:id><gtr:otherNames>Yarnold J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>5aa11fd5a1af13.74700710</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9636D6A-875E-4C5D-B6E5-5AD4448FD432</gtr:id><gtr:title>The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e46bc9eb30d08d17dc3b248661226e6"><gtr:id>7e46bc9eb30d08d17dc3b248661226e6</gtr:id><gtr:otherNames>START Trialists' Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>031ED488133</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A97A956-3EB5-40CF-862A-5F49C1D781EF</gtr:id><gtr:title>The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86024c1d9431f553e3e1d02c4cc95031"><gtr:id>86024c1d9431f553e3e1d02c4cc95031</gtr:id><gtr:otherNames>Haviland JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>pm_15613_23_24055415</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>29DC11D1-2723-446B-AB2A-55DBFE9D7911</gtr:id><gtr:title>Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/506a277a3fd26a248bbc73e48feb8711"><gtr:id>506a277a3fd26a248bbc73e48feb8711</gtr:id><gtr:otherNames>Barnett GC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>pm_15613_23_23199655</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6D38F4F-5DA7-4918-B827-AAA2AD1D9BB8</gtr:id><gtr:title>Homologous recombination mediates cellular resistance and fraction size sensitivity to radiation therapy.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b0e489750c6d225b340afa2b876064f7"><gtr:id>b0e489750c6d225b340afa2b876064f7</gtr:id><gtr:otherNames>Somaiah N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>5aa11e9b553c82.85594356</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4639C8B-5298-4FE7-8C33-B820B56CBDBF</gtr:id><gtr:title>Intensity-modulated Radiotherapy for the Treatment of Breast Cancer.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4da0e2ef9b0cc75e7cb034fd9e00a0cb"><gtr:id>4da0e2ef9b0cc75e7cb034fd9e00a0cb</gtr:id><gtr:otherNames>Coles CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>5aa11e9bbe5a95.30124587</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5454A443-5305-4F8C-B9A1-07F31DB28B5E</gtr:id><gtr:title>Cytokine levels as biomarkers of radiation fibrosis in patients treated with breast radiotherapy.</gtr:title><gtr:parentPublicationTitle>Radiation oncology (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/840ef5fc992da770f0f63449f3d0f63a"><gtr:id>840ef5fc992da770f0f63449f3d0f63a</gtr:id><gtr:otherNames>Westbury CB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1748-717X</gtr:issn><gtr:outcomeId>5aa11fd56c03b3.31597727</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD3D7C06-72A6-4FAD-9606-11B4CD7A94D7</gtr:id><gtr:title>The UK HeartSpare Study: randomised evaluation of voluntary deep-inspiratory breath-hold in women undergoing breast radiotherapy.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e22b1d43bc12a5173d191f77a36766b"><gtr:id>5e22b1d43bc12a5173d191f77a36766b</gtr:id><gtr:otherNames>Bartlett FR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>5aa11e9b879e34.60024609</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B5EEFF0-09EF-4293-AC5C-B57F80865B6F</gtr:id><gtr:title>Does participation in clinical trials influence the implementation of new techniques? A look at changing techniques in breast radiotherapy in the UK.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f9d854988cf3675d94896a0e22fdfe4"><gtr:id>8f9d854988cf3675d94896a0e22fdfe4</gtr:id><gtr:otherNames>Venables K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>pm_15613_23_22795830</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C277C12-A801-4AE2-B2E3-5A4A5183302A</gtr:id><gtr:title>Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow-up in the randomised Standardisation of Breast Radiotherapy (START) trials.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf7159f832955f48b7a64134732f6f2e"><gtr:id>cf7159f832955f48b7a64134732f6f2e</gtr:id><gtr:otherNames>Hopwood P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>FpYQmeEdMeM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C953F50B-1AE7-498A-B219-78D7DDEEA8AB</gtr:id><gtr:title>The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START Trial (Standardisation of Breast Radiotherapy Trial).</gtr:title><gtr:parentPublicationTitle>Breast (Edinburgh, Scotland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf7159f832955f48b7a64134732f6f2e"><gtr:id>cf7159f832955f48b7a64134732f6f2e</gtr:id><gtr:otherNames>Hopwood P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0960-9776</gtr:issn><gtr:outcomeId>312AAE0DF56</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BCE0EEAA-8A36-4C18-A6A9-5ED94F3720E4</gtr:id><gtr:title>Haste makes waste: are the data regarding TARGIT-A IORT ready for prime time?</gtr:title><gtr:parentPublicationTitle>Breast cancer research and treatment</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aac0af47c1973a066a07d222438e8599"><gtr:id>aac0af47c1973a066a07d222438e8599</gtr:id><gtr:otherNames>Kaidar-Person O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0167-6806</gtr:issn><gtr:outcomeId>5aa11fd421a977.04174144</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE58D641-2ADC-4768-A0B2-0D517FB455FA</gtr:id><gtr:title>A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/506a277a3fd26a248bbc73e48feb8711"><gtr:id>506a277a3fd26a248bbc73e48feb8711</gtr:id><gtr:otherNames>Barnett GC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>5aa11fd5d5f3b2.64510115</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08BC560C-42D1-4FA5-8399-8FD982DA1661</gtr:id><gtr:title>Changes in radiotherapy fractionation - breast cancer.</gtr:title><gtr:parentPublicationTitle>The British journal of radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/580e6eb65d401ba7b3943179f1d0ad35"><gtr:id>580e6eb65d401ba7b3943179f1d0ad35</gtr:id><gtr:otherNames>Yarnold J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0007-1285</gtr:issn><gtr:outcomeId>5aa11b63076182.96621399</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5EB38EAD-26F4-4245-92DF-0C4BBAA86FB0</gtr:id><gtr:title>Response to D. Woolf and M. Keshtgar's reply to: breast radiotherapy and heart disease - where are we now?</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e22b1d43bc12a5173d191f77a36766b"><gtr:id>5e22b1d43bc12a5173d191f77a36766b</gtr:id><gtr:otherNames>Bartlett FR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>5aa11e9a5278a9.95947556</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>899EF04E-F90C-49E9-9355-0A7F62E32B04</gtr:id><gtr:title>The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e46bc9eb30d08d17dc3b248661226e6"><gtr:id>7e46bc9eb30d08d17dc3b248661226e6</gtr:id><gtr:otherNames>START Trialists' Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>B5BA2F1990F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55FBD305-4FD3-4E5D-AEC7-89AF5BDAC6A0</gtr:id><gtr:title>Multileaf collimation cardiac shielding in breast radiotherapy: Cardiac doses are reduced, but at what cost?</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e22b1d43bc12a5173d191f77a36766b"><gtr:id>5e22b1d43bc12a5173d191f77a36766b</gtr:id><gtr:otherNames>Bartlett FR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>5aa11e9a9c6877.54089969</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>265CCEEA-4791-41A1-8FC5-10EA6879E141</gtr:id><gtr:title>Dosimetry and field matching for radiotherapy to the breast and supraclavicular fossa.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6b9a41bdc7e102320c48c4c3c51c8189"><gtr:id>6b9a41bdc7e102320c48c4c3c51c8189</gtr:id><gtr:otherNames>Miles EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>263387D9465</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4EA5B094-4F83-4D4D-AA02-460028938AD4</gtr:id><gtr:title>Correlation between DNA damage responses of skin to a test dose of radiation and late adverse effects of earlier breast radiotherapy.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b0e489750c6d225b340afa2b876064f7"><gtr:id>b0e489750c6d225b340afa2b876064f7</gtr:id><gtr:otherNames>Somaiah N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>5aa11cfb7642c1.38621873</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C7CCFFF-2170-476B-AB54-E92804D53DC3</gtr:id><gtr:title>OC-0392: Tumour characteristics associated with local relapse after hypofractionated radiotherapy in early breast cancer</gtr:title><gtr:parentPublicationTitle>Radiotherapy and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b0e489750c6d225b340afa2b876064f7"><gtr:id>b0e489750c6d225b340afa2b876064f7</gtr:id><gtr:otherNames>Somaiah N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>58ad6f13b3f1d1.70178311</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4194BA81-E779-4A96-999D-C592919D0C01</gtr:id><gtr:title>The course of anxiety and depression over 5 years of follow-up and risk factors in women with early breast cancer: results from the UK Standardisation of Radiotherapy Trials (START).</gtr:title><gtr:parentPublicationTitle>Breast (Edinburgh, Scotland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf7159f832955f48b7a64134732f6f2e"><gtr:id>cf7159f832955f48b7a64134732f6f2e</gtr:id><gtr:otherNames>Hopwood P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0960-9776</gtr:issn><gtr:outcomeId>BW7W43dpkVX</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G9600656</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>6FFAED28-939F-4795-9FD1-98511549B3B8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.5  Radiotherapy</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>